Output Catalog
ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.
-
Output Type
-
Program
-
CRN Team Name
-
Theme
Characterizing dysbiosis of the Parkinson’s disease gut microbiome using shotgun metagenomics
Parkinson's disease is a progressive neurodegenerative condition with altered gut microbiome composition. A study analyzed fecal samples from 490 PD patients and 234 healthy individuals to understand dysbiosis at a detailed level.
CryoEM structures of amplified alpha-synuclein fibril class A type I with extended core from DLB case I
Protein fibril classification for Homo sapiens expressed in Escherichia coli BL21(DE3) without mutations.
CryoEM structure of amplified alpha-synuclein fibril class A type I with compact core from DLB case III
Protein fibril classification for Homo sapiens expressed in Escherichia coli 'BL21-Gold(DE3)pLysS AG without mutations.
CryoEM structure of amplified alpha-synuclein fibril class A type I with extended core from DLB case VII
Protein fibril classification for Homo sapiens expressed in Escherichia coli 'BL21-Gold(DE3)pLysS AG without mutations.
CryoEM structure of amplified alpha-synuclein fibril class A type I with extended core from DLB case X
Protein fibril classification for Homo sapiens, expressed in Escherichia coli strain BL21-Gold(DE3)pLysS AG without mutations.
CryoEM structures of amplified alpha-synuclein fibril class B type II with extended core from DLB case I
Protein fibril classification in Homo sapiens expressed in Escherichia coli BL21(DE3) without mutations.
CryoEM structure of amplified alpha-synuclein fibril class B type I with extended core from DLB case VII
Protein fibril classification in Homo sapiens, expressed in Escherichia coli 'BL21-Gold(DE3)pLysS AG system without mutations.
CryoEM structures of amplified alpha-synuclein fibril class B mixed type I/II with extended core from DLB case II
Protein fibril from Homo sapiens expressed in Escherichia coli strain BL21-Gold(DE3)pLysS AG with no mutations reported.
CryoEM structures of amplified alpha-synuclein fibril class B type I with compact core from DLB case III
Protein fibril classification for Homo sapiens expressed in Escherichia coli 'BL21-Gold(DE3)pLysS AG without mutations.
CryoEM structure of amplified alpha-synuclein fibril class B mixed type I/II with extended core from DLB case V
Protein fibril classification for Homo sapiens, expressed in Escherichia coli 'BL21-Gold(DE3)pLysS AG without mutations.
CryoEM structure of amplified alpha-synuclein fibril class B type II with extended core from DLB case VII
Protein fibril from Homo sapiens expressed in Escherichia coli BL21-Gold(DE3)pLysS AG without mutations.
CryoEM structure of amplified alpha-synuclein fibril class B type I with extended core from DLB case X
Protein fibril classification for Homo sapiens using Escherichia coli 'BL21-Gold(DE3)pLysS AG expression system with no mutations identified.
Alpha-synuclein fibril from spontaneous control
Protein fibril from Homo sapiens expressed in Escherichia coli BL21-Gold(DE3)pLysS AG without mutations.
Examining the brain’s response to intestinal permeability and inflammation in the dextran sulfate sodium-induced colitis model.
Mice were treated with DSS under various schedules to study colitis. Tissues from colon and brain regions were analyzed using RNA sequencing to understand molecular changes linked to gut leakiness and colitis progression.
Alpha-synuclein overexpression can drive microbiome dysbiosis in mice
Persons with PD have a distinct gut microbe composition. Studies on gut microbiome changes before and during PD are limited. Overexpression of α-synuclein in mice alters gut bacteria with age, suggesting a link between microbiome and PD pathology.
